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he exocytotic fusion of vesicles with the plasma membrane is a fundamental event in neuronal and endocrine 
systems, facilitating the release of active substances like neurotransmitters and hormones. his is a sequential pro-
cess that initially involves vesicle transport to the membrane mediated by cytoskeletal proteins1,2, their docking at 
the membrane and inally, their fusion and the release of their cargo (e.g., neurotransmitters) through the speciic 
interaction of SNARE proteins (soluble N-ethylmaleimide sensitive factor attachment protein receptor), and of 
the lipids that constitute the vesicular and plasma membrane3,4.
he relatively passive role of lipids assumed in the traditional model of exocytosis that is based on the catalytic 
activity of fusogenic proteins has evolved in recent times, whereby lipids are now considered to be more active 
elements in neurosecretion5–7. In this regard, it is important to note the role of signalling lipids released by the 
activity of phospholipases as direct modulators of the SNARE fusion machinery, over and above the role of struc-
tural lipids. For example, arachidonic acid (AA) released from phospholipid membranes upregulates syntaxin-1 
promoting the incorporation of this protein into SNARE complexes8,9. Moreover, the sphingolipid backbone that 
may be released, sphingosine, interacts with the vesicular SNARE synaptobrevin to enhance the formation of the 
exocytotic fusion complex, thereby enhancing the release of neurotransmitters and hormones10,11.
Interestingly, the sphingomimetic drug FTY-720 (Fingolimod), a drug approved for the treatment of multiple 
sclerosis (MS)12, also increased the formation of the ternary SNARE complex and augmented neuroendocrine 
secretion13. Indeed, more evidence appeared in recent years suggesting that this compound accumulates in cells 
of the CNS, modulating the activity of neurons and astrocytes14,15, potentially making it suitable to treat a variety 
of neurological syndromes like ischemia, stroke and neurodegeneration16–18. Furthermore, this drug has been also 
proposed for the treatment of neuronal cancers given its potential to induce the death of neuroblastoma cells19.
In view of the potential of this drug to interfere with multiple molecular mechansims associated with a vari-
ety of syndromes, we further studied the possible efects and targets of FTY-720 on the behaviour of chromain 
cells, a well established exocytotic neuroendocrine model1,20,21. Our results show that FTY-720 not only afects 
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secretory process but also, it induces the homotypic and heterotypic fusion of organelles in the cytosol, impairing 
mitochondrial function and provoking cell death.
Results
	Ǧ ? ? ?ơƥǤ Among the drugs 
derived from the structure of signalling lipids, FTY-720 is an analogue of sphingosine that has been used exten-
sively to produce immunosuppression22 and as such, it has been approved for the treatment of MS12. As a result, 
we were prompted to study whether, in addition to its immune mechanisms, this compound also afects exocy-
tosis in a similar manner to signalling lipids10,11,23,24. To test this, chromain cells in culture were stimulated by 
depolarization with a high KCl bufer and their secretory activity was studied by amperometry25,26. he num-
ber and frequency of vesicular fusions were analysed in amperometric recordings from cells before and ater 
treatment with FTY-720 (20 µM) for 15 min, an optimal concentration that enhances SNARE complex forma-
tion (Fig. 1B)13. FTY-720 provoked a characteristic enhancement in the number of secretory events in cells, irst 
because basal fusion was observed in the absence of stimulation and second, because the secretory events elicited 
by cell depolarization are clearly enhanced relative to untreated control cells (Fig. 1A,B). In addition, FTY-720 
also seemed to increase the amplitude of the individual amperometric peaks when analysed using the Quanta 
Analysis program27. Ater averaging 900 or more events from individual cells in at least 3 diferent cultures 
(Fig. 1C), it was clear that treatment with FTY-720 provoked a 2.5 fold enhancement in the quantal amount of 
catecholamines released per individual event (charge obtained from peak integration, Q value in molecules per 
event) relative to control untreated cells (Fig. 1D).
he spread in the distribution indicated that secretory events occurred in which less vesicular content was 
released and those with a much larger quantal content, characterized by prolonged opening of the fusion pore 
(Fig. 1E). herefore, FTY-720 enhanced single vesicle fusion with functional characteristics resembling that pro-
duced by its physiological counterparts, AA and sphingosine23,24. Accordingly, treatment with this drug means 
that cell stimulation produces more fusion events, and it enhances quantal secretion by provoking the release of 
microvesicles as well as vesicles with higher content. Indeed, the average release was dominated by this latter efect 
causing an enhancement in the vesicular content released per event.
Interestingly, the release of vesicles was clearly afected by repetitive stimulations, which relected an impair-
ment of both control and FTY-720 treated cells to recruit new vesicles (examples in Fig. 1F). Averaging these 
responses ater trace integration, showed a clear decrease in the mean charge released in the second and sequent 
pulses in relation with the initial one in both control and FTY-treated cells (Fig. 1G). In fact, the mean charge 
released obtained during the 3rd and 4th pulses was similar in both experimental conditions (n.s. values, Fig. 1G). 
his impairment in vesicle recruitment is related to the reduced vesicle and F-actin mobility induced by FTY-
720, as witnessed by confocal luorescence microscopy (data not shown) and consistent with earlier data from 
astrocytes28.
	Ǧ ? ? ?ƥ
Ǥ Changes in the vesicular 
content released following treatment with FTY-720 could be due to altered chromain granule size or content and 
therefore, we studied this possibility using luorescence confocal microscopy of chromain cells expressing the 
vesicular marker NPY, as indicated elsewhere29. Interestingly, ater a 10–15 min treatment with FTY-720 (20 µM) 
there was a reduction in the number of the vesicles labelled with mRFP coupled NPY (red luorescence, Fig. 2). 
Measuring the average number of vesicles in cells showed there was a signiicant reduction ater as little as 5 min 
in the presence of FTY-720, reaching a 30–40% decrease ater a 10–15 min treatment. In addition, there was a 
decrease in the average size of the granules following exposure to FTY-720, which could again be detected as 
soon as 5 min ater incubation with this drug, and that reached a 30% decrease in area (50% reduction in volume) 
ater a 10 min treatment. Consequently, we detected an early change in the formation of microvesicles following 
incubation with FTY-720 and a concomitant decrease in the number of vesicles 15 min later. hese alterations 
would support the appearance of microvesicle fusions, yet they would appear to contradict the overall increase 
in the size of the vesicular content released per event. However, it is important to bear in mind the simultaneous 
change in the mitochondrial structure evident following Mitotracker green labelling (Fig. 2E), associated with an 
increase in mitochondrial size (Fig. 2F) and a decrease in their number (Fig. 2G). In addition, these organelles 
shited from their characteristic elongated form to a shortened and somewhat rounded appearance ater a 15 min 
treatment with FTY720. his observation was supported by an increase in the mitochondria’s roundness (Fig. 2H) 
and a decrease in their Aspect Ratio (AR, ratio of the longer axis over the shorter one: Fig. 2I). Hence, FTY-720 
provokes a clear change in the morphology of the mitochondria that parallels the decrease in the number of 
chromain vesicles.
	-
	Ǧ ? ? ?Ǥ he mitochondrial and vesicle populations are particularly dense in the corti-
cal area of chromain cells in culture30,31 and thus, changes in the destiny of vesicles in the sub-plasmalemma 
region (up to 150–200 nm from the cell membrane) were tracked by total internal relection luorescent micros-
copy (TIRFM)32,33. During the initial 5–10 min ater exposure to FTY-720, NPY-mRFP labelled vesicles were 
apparently smaller in size but later, these luorescent organelles appeared to become more elongated and larger 
(Fig. 3A,B). hese latter changes were accompanied by a dramatic reduction in the number of vesicles observed, 
consistent with the confocal microscopy data and with the increase in the size of the labelled organelles measured 
by mean area determination (Fig. 3E). Consequently, TIRFM experiments revealed an intriguing change in the 
properties of vesicles, with an initially shit towards the formation of microvesicles followed by their apparent 
fusion, both homotypic fusion or heterotypic fusion with other major cortical membrane structures, which was 
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Figure 1. Secretory responses of chromain cells exposed to FTY-720. (A,B) Amperometric measurements 
from cultured bovine chromain cells stimulated by depolarization with a 59 mM KCl solution: control cells 
(A) and cells treated with a 20 µM FTY-720 for 15 mins (B). (C) Averaged amperometric fusion events and 
parameters from control (N = 1262 events) and FTY-720-treated cells (N = 901 events). (D) FTY-720 enhances 
the quantal amount of catecholamines released per single event. (E) Distribution of the quantal events in control 
and FTY-720 treated cells. (F) Example of amperometrical responses to cell depolarization in repetitive 10 s 
pulses. (G) Mean secretory responses obtained by amperometry trace integration during each pulse (charge) 
in both control and FTY-treated cells.Statistical signiicance was assessed with a Mann-Whitney U-Test: 
**P ≤ 0.005. ***P ≤ 0.0001.
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relected in a reduction in the number of vesicles observed under evanescent ield and in the formation of elon-
gated structures.
Evidence of cross-fusion between chromain granules and mitochondria (heterotypic fusion) was obtained 
by analysing the co-localization of the NPY-mRFP vesicular labelling (red luorescence in Fig. 3C) and that of 
mitotracker green in mitochondria (green luorescence in Fig. 3C) in sequential confocal microscopy images. 
FTY-720 appears to induce cross-fusion of these organelles as their luorescent signals appear to co-localize, 
detected as a yellow colour in the merged images (Fig. 3C). his co-localization was further supported by the 
Pearson coeicient that correlated the distribution of the red and green luorescence signals (Fig. 3D), with 
Figure 2. Morphometric changes of vesicles and mitochondria in control and FTY-720 treated cells. (A) 
Time-lapse confocal luorescence microscopy of a representative cultured chromain cell expressing RFP-NPY 
(red) to show vesicles from control and FTY-720 treated cells (5, 10 and 15 min). (B) Vesicular size frequency 
distribution comparing all conditions (C; FTY720 5,10 and 15 min) by size. (C,D) Box and whiskers and 
scatter plot vertical graphs of vesicle area (C) and number (D) by condition (N = 10 cells; Ncontrol = 686, NFTY720 
5min = 554, NFTY720 10min = 419, NFTY720 15min = 393 vesicles). (E) Time-lapse confocal luorescence microscopy 
images from a representative live cultured chromain cell labeled with MitoTracker green to identify the 
mitochondria in control and FTY-720 treated cells (5, 10 and 15 min). (F–I) Box and whiskers vertical graphs 
of the mitochondrial area (F), number (G), roundness (H) and aspect ratio (I) per condition (N = 5 cells: 
Ncontrol = 804, NFTY720 5min = 621, NFTY720 10min = 424, NFTY720 15min = 350 mitochondria). Box and whiskers graph 
shows the mean as the central box line, the SEM as the box limits (top and bottom) and the amplitude variability 
through the whiskers (box emergent lines). Statistical signiicance was assessed by a Kruskal-Wallis Test: n.s., 
non-signiicant (P ≥ 0.05), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Scale bars represent 1 µm.
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enhanced co-localization as the FTY-720 treatment increases, shiting the Pearson coeicient from 0.12 in the 
absence of FTY-720 to 0.36, 0.58 and 0.70 ater a 5, 10 and 15 min treatment with FTY-720 (Fig. 3F).
Ƥƥǡ-
Ǥ he co-localization detected above was a strong evidence that FTY-720 
induced heterotypic vesicular and mitochondrial fusion, such that we tested these initial observations by per-
forming electron microscopy (EM) on control and FTY-720 treated cells. In electron micrographs of control 
untreated cells, relatively homogeneous electron-dense chromain granules were evident in the cytosol of the 
cells, and there was a lower density of mitochondria with a weaker electron density, identiied by their shape and 
Figure 3. Colocalization of organelles during FTY-720 treatment. (A) Time-lapse TIRF microscopy images 
from a representative cultured chromain cell expressing RFP-NPY (red) to detect vesicles at the plasma 
membrane of control and FTY-720 treated cells (5, 10 and 15 min). (B) Vesicular masks at plasma membrane 
in each condition. (C) Time-lapse confocal luorescence images from a representative live cultured chromain 
cell labelled with MitoTracker green to visualize mitochondria, and expressing RFP-NPY (red) to detect vesicles 
in control and FTY-720 treated cells (5, 10 and 15 min). (D) Representative cytoluorograms per condition 
(Y axis for red luorescence and X axis for green luorescence). he black lines indicate the luorescence 
colocalization as a direct correlation of the line’s slopes. (E) Mean ± SEM values of the cortical vesicular mask 
area per condition (N = 5 cells: Ncontrol = 106, NFTY720 5min = 59, NFTY720 10min = 37, NFTY720 15min = 19 masks). (F) 
Mean ± SEM values of the Pearson’s Correlation Coeicient per condition (N = 5 cells: N = 10 points/cell). 
Statistical signiicance was assessed with a Kruskal-Wallis Test: ***P ≤ 0.001. Scale bars represent 1 µm.
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the presence of internal cristae (Fig. 4A). Ater incubating the cells for 15 min with FTY-720 (20 µM), the size of 
the electron-dense vesicles was clearly reduced (measuring more than 1,000 vesicles in 11 cells: Fig. 4B), with 
a 50% fall in their mean circular area (Fig. 4C). In addition, there were 50% fewer vesicles in the cytosol of the 
treated chromain cells (n = 11 cells, P < 0.001: Fig. 4C).
In parallel with the changes detected in the size and number of chromain vesicles, we also found that  FTY-
720 altered the shape and area of the mitochondria (Fig. 4B), which became rounder (Fig. 4D) in conjunction 
with a four–fold increase in their area (Fig. 4D). Consequently, the EM images supported the data gathered by 
confocal and TIRF microscopy, proving the simultaneity of the changes observed in chromain vesicles and 
mitochondria when cells were treated with FTY-720.
In the same EM images, some of the events leading to the eventual fusion of organelles were evident. For 
example, the initial phase of vesicular homotypic fusion was observed (Fig. 4E), with the formation of vesicular 
contacts between two (Fig. 4F, second row) or three vesicles (third row). Subsequently, there was a redistribu-
tion of the dense core of the granules, suggesting a partial loss of the vesicular content that may even reach 
total release. Following the destiny of these multivesicular fusions, they commonly seemed to relect complete 
fusion with mitochondria (Fig. 4G, second row), involving the fusion of 3 to 5 vesicles per mitochondria and the 
internalization of the vesicular content in the mixed organelle, without any loss of its compact aspect (Fig. 4G,H, 
second row). In other images, heterotypic fusion of individual chromain vesicles and mitochondria was evident 
as a possible early event that did not require the prior homotypic fusion of vesicles (Fig. 4H, second row).
Ater the formation of these mixed organelles, there was evidence of the fusion of these mixed organelles in 
other images (Fig. 4G, third and fourth row). As such, “giant” round organelles with many characteristics of mito-
chondria (such as the internal cristae) were ultimately formed, incorporating the dense core of several chromain 
vesicles (Fig. 4G,H, fourth and ith rows).
	Ǧ ? ? ?ǡ
Ǥ To test whether the alterations to chromain cells and mitochondria caused by FTY-720 
are mediated by SNARE-dependent fusogenic properties, as demonstrated for exocytosis in diferent systems13, 
chromain cells were transfected with the wild-type SNAP-25 linked to GFP or a truncated SNAP-25 ∆9 that did 
not prevent SNARE complex formation but reduced secretory activity, mimicking botulinum neurotoxin type A 
activity34,35. In addition, some cells also expressed NPY-mRFP to visualize vesicles, testing the ability of FTY-720 
to alter their size and number. Over-expression of the truncated SNAP-25 partially prevented (50% reduction) 
the formation of microvesicles (Fig. 5A,C,E) and the reduction in the chromain granule population provoked 
by FTY-720 (Fig. 5D,F). In addition, mitochondrial labelling of the cells (Fig. 5B) demonstrated that SNAP-25 
∆9 over-expression partially prevented the change in area (Fig. 5G,I) and in the roundness of mitochondria 
(Fig. 5H,J). Together, these results strongly suggest that a late phase of SNARE-mediated fusion is involved in 
the alterations sufered by these organelles as a result of FTY-720-enhancement of SNARE complex formation13.
ơǤ To assess the 
functional consequences of the alterations to the organelles produced by FTY-720, we evaluated its efects on 
the mitochondrial redox potential by measuring the intensity of mitotracker red luorescence that is sensitive to 
this parameter36. here was an obvious reduction in the Mitotracker red labelling in cells incubated with FTY-
720 (20 µM), both in terms of intensity and luorescence density (Fig. 6A). his reduction in intensity reached 
around a 70% decrease following a 15 min incubation with FTY-720 (Fig. 6C), indicative of a strong efect on the 
mitochondrial redox potential.
Impaired mitochondrial function will almost certainly afect cell survival and therefore, we studied the main-
tenance of cell integrity by Trypan Blue staining (Fig. 6B). As expected, ater a 10 min incubation with FTY-720 
around 20% of cells took up this dye, indicative of the disruption of their cell membrane (Fig. 6D). Moreover, ater 
a 15 min incubation with FTY-720 (as used in most experiments), followed by a 2 h recovery in fresh medium, we 
detected 50% cell death relative to the controls. Finally, 24 h ater this 15 min incubation even more cell mortality 
was evident, afecting 80% of the cell population. hus, it appeared that the rapid and dramatic alterations to 
mitochondrial morphology caused by FTY-720 via their heterotypic fusion with vesicles was accompanied by a 
dissipation of their redox potential, which led ultimately to largescale mortality of the cultured cells.

	Ǧ ? ? ?ƪ
Ǥ FTY-720, also known as Fingolimod, is a structural analogue of sphingosine with immunosupres-
sant properties22 that has been approved and is used extensively to treat relapsing remitting MS12,37. Its activity 
is related to the capacity of sphingosine-1P to interact with receptors mediating lymphocyte homing, thereby 
avoiding immunosupression38. Nevertheless, in the last 5 years evidence has accumulated that this compound 
also inluences a variety of processes, including neuronal gene expression, axon growth and degeneration39. hese 
efects may not only be associated with the neuroprotective beneits of this drug40 but also, its therapeutic efects 
in ischemia, excitotoxicity and memory recovery41–43. Nevertheless, this drug could also negatively afect neurons, 
inducing apoptosis by altering calcium signalling and mitochondrial membrane potentials, efects that could be 
useful to sensitize neuroblastoma cells to anti-.neoplastic drugs19.
In terms of the mechanisms that might underlie such a variety of neuronal efects, we recently demonstrated 
that FTY-720 mimics sphingosine in its activation of synaptobrevin to promote SNARE complex formation, 
enhancing exocytosis in neuronal and neuroendocrine models at concentrations around 10–20 µM, similar to 
that found for sphingosine13. Here, we show that FTY-720 enhances quantal vesicle release, consistent with the 
results obtained in rat hippocampal neurons in culture13. However, rather than a simple increase in the release 
of neurotransmitter per event, we observed the formation and fusion of microvesicles, events that ultimately 
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Figure 4. Electron microscopy shows organelle transformation mediated by FTY-720 induced fusions. (A,B) 
EM micrographs of representative cultured control chromain cells (A), and ater incubation with FTY-720 
for 15 min (B). (C) Mean ± SEM vesicle number (white bars) and area (black bars) per condition (Ncontrol = 6 
cells, 1235 vesicles; NFTY720 15min = 6 cells, 542 vesicles). (D) Mean ± SEM values of mitochondrial roundness 
(white bars) and area (black bars) per condition (Ncontrol = 6 cells, 932 mitochondria; NFTY720 15min = 6 cells, 
406 mitochondria). (E) EM micrographs from cultured control chromain cells and ater FTY-720 (15 min) 
showing diferent fusion levels (I to III) ater treatment. (F–H) Ampliied images of representative cytoplasmic 
sections including examples of all types of fusion (rows) and levels (columns; I to III) between vesicles (V), 
and mitochondria (M). Red stars and boxes indicate interaction between elements. Statistical signiicance was 
assessed with a Mann-Whitney U-Test: **P ≤ 0.01, ***P ≤ 0.001. Scale bars represent 2 µm (A,B,E) and 1 µm 
(F–H).
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provoke an increase in the mean exocytotic release. hese complex efects on exocytosis seem to agree well with 
the efects of sphingosine, enhancing release from microvesicles and full chromain granules in bovine23 and rat 
chromain cells24. Interestingly, this efect was also found in lactotrophs44, suggesting that the size of vesicles was 
a major factor inluencing the efect of sphingosine, favouring the “kiss and run” fusion of microvesicles and the 
full collapse of larger dense vesicles.
Our confocal and EM studies clearly show that microvesicles are produced rapidly in the cytosol following 
FTY-720 treatment, a process that is dependent on SNARE activity. Indeed, some of these vesicles undergo homo-
typic fusion that could lead to exocytotic fusion, releasing distinct levels of catecholamines, as detected by single 
cell amperometry.
	Ǥ In searching for possible 
changes in chromain vesicle size to explain the variation in quantal exocytosis, we found important alterations 
to mitochondrial size and aspect that relect their heterotypic fusion. Hence, this is the irst report of heterotypic 
fusion linked to the action of an approved drug. he mechanisms underlying this organelle fusion involve SNARE 
proteins present in the membrane of chromain granules. he observation of homotypic granular fusion con-
comitant with heterotypic fusion during the initial phase of FTY-720 treatment strongly suggests the SNAREs are 
incorporated into the mitochondrial membranes, in stark contrast to their normal distribution. Subsequently, 
mitochondria also undergo homotypic fusion to generate giant altered forms of these organelles that include 
several dense granule cores (normally between 2 and 5). Since this is a late event, it might be related to the incor-
poration of SNAREs during heterotypic fusion.
      	Ǧ ? ? ?     
Ǥ he data presented here clearly support a new mechanism that explains the efects of FTY-720 on 
neuronal and neuroendocrine cells, and that is driven by the enhanced fusogenic activity of SNAREs induced 
by micromolar concentrations of this drug13. Accordingly, FTY-720 may difuse across the plasma membrane 
Figure 5. SNAP-25 is involved in organelle fusion induced by FTY-720. (A,B) Time-lapse confocal luorescence 
microscopy images from representative cultured chromain cells expressing WT and the truncated form 
GFP-SNAP-25 ∆9 (green), combined with RFP-NPY (red) expression to show vesicles (A) and MitoTracker 
Red CMXRos labeling to detect mitochondria (B), in control cells and ater FTY-720 treatment (5, 10 and 
15 min). (C,D) Mean ± SEM values of vesicular area (C) and number (D) for WT SNAP-25 cells (N = 5 cells: 
Ncontrol = 686, NFTY720 5min = 507, NFTY720 10min = 419, NFTY720 15min = 263 vesicles). (E-F) Mean ± SEM values of 
vesicular area (E) and number (F) for ∆9 SNAP-25 cells (N = 5 cells: Ncontrol = 601, NFTY720 5min = 587, NFTY720 
10min = 584, NFTY720 15min = 490 vesicles). (G,H) Mean ± SEM values of mitochondrial area (G) and roundness 
(H) for WT SNAP-25 cells (N = 5 cells: Ncontrol = 665, NFTY720 5min = 612, NFTY720 10min = 420, NFTY720 15min = 341 
mitochondria). (I,J) Mean ± SEM values of mitochondria area (I) and roundness (J) for ∆9 SNAP-25 cells 
(N = 5 cells: Ncontrol = 579, NFTY720 5min = 582, NFTY720 10min = 557, NFTY720 15min = 497 mitochondria). Statistical 
signiicance was assessed with a Two-way ANOVA Test: n.s. non-signiicant (P ≥ 0.05), *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001. Scale bars represent 1 µm.
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to accumulate in the cytosol, where it could mimic the activity of sphingosine to promote SNARE complex for-
mation, inluencing synaptobrevin availability13. he formation of these fusogenic complexes enhances the exo-
cytotic fusion of secretory vesicles, initially augmenting neuroendocrine secretion as occurs with sphingosine 
derivatives10,23,24. However, the concomitant inhibition of F-actin cytoskeleton mediated transport limits the 
availability of vesicles and their transport from internal pools, as demonstrated here and in accordance with data 
from astrocytes28. hus, FTY-720 has a complex efect on exocytosis, promoting the release of ready releasable 
pools of vesicles but impairing the recruitment of other pools from the cell’s interior (see scheme in Fig. 7).
Interestingly, SNARE activity is also involved in the formation of microvesicles by membrane ission and 
homotypic fusion of granules in the cytosol (Fig. 7). he enhanced fusogenic properties of vesicles also leads 
to the heterotypic fusion of vesicles with mitochondria and inally, to the homotypic fusion of altered mito-
chondria. As evident in EM images, the alterations to mitochondrial structure are so dramatic as to collapse the 
Figure 6. Altered mitochondrial membrane potential and reduced cell viability promoted by FTY-720. (A) 
Time-lapse confocal luorescence microscopy images from a representative control and FTY-720 treated 
cultured chromain cell (t0, 5, 10 and 15 min) labeled with MitoTracker Red CMXRos to identify mitochondria. 
(B,C) Mean ± SEM mitochondrial membrane potential in terms of luorescence intensity (white bars) 
and density (black bars) for control condition (B) (Ncontrol = 5 cells; NT0 = 797, N5min = 781, N10min = 764, 
N15min = 760 mitochondria) and FTY720 treatment (C) (NFTY720 = 5 cells; NTO = 804, N5min = 621, N10min = 424, 
N15min = 350 mitochondria). (D) Time-lapse optical microscopy images from representative chromain cell 
cultures under control conditions and ater FTY-720 treatment for 15 min evaluated at diferent times: 15 min, 
4 h, 12 h, and 24 h. (E) Mean ± SEM of the viability of control (white bars) and FTY-720 treated (black bars) cells 
evaluated at distinct times (Nt0 = 467 (C), 488 (FTY); N5min = 503 (C), 453 (FTY); N10min = 497 (C), 468 (FTY); 
N15min = 510 (C), 505 (FTY); N1h = 477 (C), 464 (FTY); N2h = 396 (C), 478 (FTY); N4h = 470 (C), 482 (FTY); 
N8h = 567 (C), 538 (FTY); N12h = 477 (C), 445 (FTY); N24h = 455 (C), 476 (FTY) cells). Statistical signiicance 
was assessed with a Mann-Whitney Test: n.s. non-signiicant, (P ≥ 0.05), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
Scale bars represent 1 µm (A) and 15 µm (B).
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mitochondrial membrane potential, which probably provokes rapid apoptosis and cell death (Fig. 7). Similar 
alterations to the redox potential of mitochondria provoked by FTY-720 have been seen in neuroblastoma cells, 
suggesting this compound induces apoptosis of these tumour cells through various signalling pathways19. In con-
clusion, as far as we know this is the irst report of drug induced heterotypic fusion of organelles that induces cell 
death. his efect must be taken in account when interpreting the efects of FTY-720, compromising the viability 
of target cells and potentially representing a valuable tool to attack populations of tumour cells of neuronal origin.

ƥǤ Chromain cells were isolated from bovine adrenal glands 
by collagenase digestion, and they were further separated from the debris and erythrocytes by centrifugation 
on Percoll gradients, as described elsewhere45–47. he cells were maintained as monolayer cultures in Dulbecco’s 
modiied Eagle’s medium (DMEM) supplemented with 10% foetal calf serum, 10 µM cytosine arabinoside, 10 µM 
5-luoro-2′-deoxyuridine, 50 IU/ml penicillin and 50 µg/ml streptomycin. he cells were harvested and plated 
at a density of 150,000 cells/cm2 in 35 mm Petri dishes (Costar), and they were used between the third and sixth 
day ater plating.
Ǥ To study secretory activity from control non-transfected 
cells and those expressing the diferent constructs, the culture medium was replaced by Krebs/HEPES (K/H) 
basal solution the pH of which was adjusted to 7.4 using NaOH (in mM): NaCl 134, KCl 4.7, KH2PO4 1.2, MgCl2 
1.2, CaCl2 2.5, Glucose 11, and Hepes 15. Carbon-ibre electrodes insulated with polypropylene and with 14 µm 
diameter tips were used to monitor catecholamine release from individual chromain granules in cells under 
superfusion26. he electrodes were positioned in close apposition to the cell surface using high precision hydrau-
lic micromanipulation, assessing cell membrane deformation with an Axiovert 135 inverted-stage microscope 
(Zeiss, Oberkochen, Germany) carrying Hofman optics (Modulation Optics, Greenvale, NY). Electrical connec-
tion was accomplished with mercury and an amperometric potential of +650 mV was applied against an Ag/AgCl 
bath reference electrode using an Axopatch 200 A ampliier (Axon Instruments Inc. Foster City, CA). he current 
product of catecholamine oxidation was digitized with an A/D converter and recorded at 400 µs/point using the 
Clampex sotware (Axon) running on a PC. Experiments were performed in cells stimulated by superfusion with 
a depolarizing 59 mM high potassium solution (obtained by isosmotically replacing NaCl with KCl), applied 
through a valve-controlled pufer tip commanded by the acquisition sotware and located near the cells studied. 
A curve itted to the non-linear models provided or implemented in the sotware (Igor Pro and Graphpad Prism) 
was used to analyse the data. Individual spike characteristics were studied using the aforementioned Quanta 
program, allowing for peak detection, integration and kinetic parameter calculations. Ater acquisition at 2 kHz, 
only well- deined narrow peaks with an amplitude higher than 5 pA were used to build event histograms. his 
ensured that the vesicle fusions analysed were produced in the proximity of the electrode and thus, complete 
Figure 7. A new mechanism of action for FTY-720 afecting neuroendocrine function and cell death. FTY-720 
accumulates in the cell cytoplasm where it can promote SNARE complex assembly and reduce F-actin mobility, 
thereby limiting vesicle transport to the plasma membrane for secretion. SNARE complex enhancement 
mediates intracellular vesicle ission. Vesicles could fuse among themselves (homotypic fusion) or with 
mitochondria (heterotypic fusion). Mixed organelles cannot maintain their membrane potential, leading to cell 
death.+Indicates potentiation and − reduction.
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oxidation of the released catecholamines was accomplished. Cell-to-cell variation was alleviated by using the 
same electrodes to measure the control cells and those exposed to FTY-720 (20 µM) for 15 min (Sigma Aldrich, 
SML0700, Lot#056M4724V), as indicated elsewhere13.
ƪƥǡǡǦ ? ?-
Ǥ Plasmids were expressed as described elsewhere48,49, using RFP-NPY (red) to identify dense-core 
vesicles and EGFP-SNAP25 (green) to study both the WT and ∆9 SNAP-25 protein. he Amaxa basic nucleofec-
tor kit was used to transfect primary mammalian neuronal cells according to the manufacturer’s instructions 
(program 0–005, Amaxa GmbH, Koehl, Germany). Moreover, cells were incubated for 15 min with MitoTracker 
Green FM (0.1 µM: Invitrogen-Molecular Probes ref M7514, Lot#1391-10) and MitoTracker Red CMXRos 
(0.2 µM: Invitrogen-Molecular Probes ref. M7512, Lot#1644639) to visualize mitochondria, as described previ-
ously30. MitoTracker labeling was used in transfected (two days post-transfection) and non-transfected cells, and 
combined with Alexa Fluor 488 (green) to locate active sites of secretion at the plasma membrane by visualizing 
DBH protein patches. All luorescent labelling was performed prior to FTY-720 treatment (20 µM: Sigma Aldrich, 
SML0700, Lot#056M4724V), except the immunolabeling.
For immunolabeling, cells were irst incubated with Mitotracker Red (CMXRos), as described above, and 
they were then treated with FTY-720 for 5 or 15 min prior to studying their basal state and that ater stimulation 
by depolarization with a 59 mM KCl solution for 30 s at room temperature (21–22 °C). Secretion was stopped by 
lowering the temperature with ice-cold bufer and the sites of secretion were labelled by immunocytochemistry 
using an anti-DBH rabbit antiserum (1/500: Merck-Millipore, ref AB1585), followed by an Alexa Fluor 488 cou-
pled donkey anti-rabbit IgG (H + L) secondary antibody (1/200: Molecular Probes, ref A21206), again in ice-cold 
bufer to prevent endocytosis.
Vesicles, mitochondria, SNAP-25 proteins and secretory sites were studied in confocal luorescence images 
from equatorial cellular sections, all obtained with an Olympus Fluoview FV300 confocal laser system mounted 
on an IX-71 inverted microscope incorporating a 100X PLAN-Apo oil-immersion objective with 1.45 NA. 
Excitation was achieved with argon and helium-neon visible light lasers, and dual luorescence was registered 
by sequential acquisition using a 488 nm argon ion (40 mW) to excite EGFP, MitoTracker green and Alexa 488, 
and with a 543 nm He/Ne 10 mW for RFP and MitoTracker Red CMXRos. A coupled perfusion system was used 
for FTY-720 treatment, administered at room temperature (22–25 °C) during time-lapse recordings for 15 min.
	ƥǤ We used transfection of the RFP-NPY plasmid, as described 
above, to label dense-core vesicles, and two days ater transfection live chromain cells were recorded by TIRF 
microscopy ater a 5 min incubation with K/H solution followed by 15 min with FTY-720 (20 µM: Sigma Aldrich, 
SML0700, Lot#056M4724V). All these solutions were applied using the perfusion system at room temperature 
(22–25 °C).
A through-the-lens TIRFM system was configured on the Olympus IX-71 inverted microscope using a 
100× PlanApo 1.45 NA Olympus TIRFM objective33. Laser illumination (543 nm He/Ne 10 mW: MellesGriot, 
Carlsbad, CA, USA) was selected using an Olympus TIRFM IX2-RFAEVA combined system, modifying the angle 
of laser incidence. In these experiments, laser intensity was kept low to prevent light-induced fusion (2–4% of 
the maximal intensity)50. TIRFM calibration was performed using 100-nm luorescent beads (Molecular Probes, 
Invitrogen Detection Technologies, Carlsbad, CA, USA). he depth of penetration for the evanescent ield was 
estimated to be around 200 nm (1/e depth of 180 ± 16 nm), mainly permitting the visualization of the static 
beads adhered to the coverslip. Fluorescence emission was acquired at a rate of 5 s per frame using an Electron 
Multiplier charge-coupled device cooled camera (C9100-02 model, Hamamatsu photonics, Japan) and the data 
was stored on an IBM compatible PC.
Ǥ Bovine chromain cell control pellets and pellets pre-treated for 
15 min with FTY-720 (20 µM: Sigma Aldrich, SML0700, Lot#056M4724V) were ixed for 2 h at 4 °C with 2.5% 
glutaraldehyde in 0.2 M cacodylate bufer [pH 7.0]. All the pellets were then washed overnight at 4 °C in a solution 
of 0.2 M cacodylate bufer, sucrose and distilled water and ater post-ixing for 2 h at 4 °C with 1% osmium tetrox-
ide in 0.2 M cacodylate bufer, and extensive washing with distilled water, the samples were stained for 1 h at 4 °C 
with 2% aqueous uranyl acetate. Subsequently, the samples were washed again, dehydrated through an ethanol 
series (30, 50, 70, 80, 96 and 99%: 15 min in each) and incubated twice for 15 min with propylene oxide at room 
temperature. Finally, the cell pellets were embedded in epoxy resin and ultra-thin sections (70 nm) were obtained 
on a Leica UC6 ultramicrotome and transferred to copper grids (200 mesh). Ater staining with uranyl acetate for 
5 min and lead citrate for 1 min, the ultrathin sections were analyzed on a JEOL 1011 80 kv transmission electron 
microscope, with a Gatan BioScam mod 792 digital camera to capture the images.
	Ǧ ? ? ?ƥǤ We used cell monolayer cultures incubated with supple-
mented DMEM (see above) and trypan blue solution (1:5: Sigma Aldrich, T6146) cultured for 24 h and evaluated 
at: t0, 5 min, 10 min, 15 min, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h. We prepared control cultures and others that were 
treated with FTY-270 (20 µM; Sigma Aldrich, SML0700, Lot#056M4724V) for 5, 10 and 15 min. In some cases, 
ater the 15 min FTY-720 treatment the culture medium was replaced by fresh DMEM-Trypan Blue to remove 
the FTY-720 and the long-term toxicity produced was studied. his evaluation consisted of quantifying cell death 
(blue cells that incorporated trypan blue through their compromised membrane) and live cells, comparing the 
control and FTY-720 treated cells at each time points. Cultures were assessed and the cells counted at each time 
point using an optical microscope coupled to a camera. he numbers of dead and live cells were used to calculate 
the cell viability (CV, %) for each condition and time, as follows:
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= + ∗CV Number of live cells Number of dead cells Number of live cells% [ /( )] 100
Ǥ he data are presented as the mean ± SEM (standard error of the mean) and the statis-
tical signiicance was determined using diferent tests based on the number of evaluation conditions, the inlu-
encing factors and the parametric nature of the data (GraphPad Prism® 4.0, GraphPad Sotware Inc., San Diego, 
CA). A Student’s T-test was used to evaluate parametric data with a single inluencing factor, and a Mann-Whitney 
U-Test for two evaluation conditions with a single inluencing factor (not assuming a Gaussian distribution). A 
Kruskal-Wallis Test was used for more than two evaluation conditions with a single inluencing factor (not assum-
ing a Gaussian distribution) and a Two way ANOVA Test was used for parametric data where there were two or 
more evaluation conditions with two inluencing factors. he statistical signiicances are included in the graphs 
as: n.s, non-signiicant (P ≥ 0.05); *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. “N” values relect the number of cells and 
organelles analyzed (vesicles and mitochondria) in each condition, and all are also included in the igure legends.
Ǥ Adrenal glands were obtained from an industrial slaughterhouse (Matadero de Orihuela 
SA) that is subject to strict regulations laid down by the Spanish Ministries of Agriculture, Industry and Health, 
and in accordance with EC guidelines. All the protocols used in this study were approved by the “Organo 
Evaluador de Proyecto” at the University Miguel Hernández, the oice in charge of overseeing the ethical issues 
associated with animal care and experimentation at our institute.
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